Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,264 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Homologous and Heterologous Boosting of the Chadox1-S1-S COVID-19 Vaccine With the SCB-2019 Vaccine Candidate: A Randomized, Controlled, Phase 2 Study.
Costa Clemens SA, Milan EP, Sprinz E, Neto JC, Pacciarini F, Li P, Chen HL, Smolenov I, Pollard A, Clemens R. Costa Clemens SA, et al. Among authors: pollard a. Open Forum Infect Dis. 2022 Aug 16;9(8):ofac418. doi: 10.1093/ofid/ofac418. eCollection 2022 Aug. Open Forum Infect Dis. 2022. PMID: 36043184 Free PMC article.
Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults.
Costa Clemens SA, Marchevsky N, Kelly S, Felle S, Eldawi A, Rajasingam R, Mahmud R, Lambe T, Voysey M, Gonzalez I, Milan EP, Justino MC, Bibi S, Aley P, Clemens R, Pollard AJ. Costa Clemens SA, et al. Among authors: pollard aj. Hum Vaccin Immunother. 2023 Aug 1;19(2):2233400. doi: 10.1080/21645515.2023.2233400. Hum Vaccin Immunother. 2023. PMID: 37438960 Free PMC article. Clinical Trial.
Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial.
Madhi SA, Kwatra G, Richardson SI, Koen AL, Baillie V, Cutland CL, Fairlie L, Padayachee SD, Dheda K, Barnabas SL, Bhorat QE, Briner C, Ahmed K, Aley PK, Bhikha S, Bhorat AE, Esmail A, Horne E, Kaldine H, Mukendi CK, Madzorera VS, Manamela NP, Masilela M, Hermanus ST, Motlou T, Mzindle N, Oelofse S, Patel F, Rhead S, Rossouw L, Taoushanis C, van Eck S, Lambe T, Gilbert SC, Pollard AJ, Moore PL, Izu A. Madhi SA, et al. Among authors: pollard aj. Lancet Infect Dis. 2023 Mar;23(3):295-306. doi: 10.1016/S1473-3099(22)00596-5. Epub 2022 Oct 20. Lancet Infect Dis. 2023. PMID: 36273491 Free PMC article. Clinical Trial.
T-cell responses induced by ChAdOx1 nCoV-19 (AZD1222) vaccine to wild-type severe acute respiratory syndrome coronavirus 2 among people with and without HIV in South Africa.
McMahon WC, Kwatra G, Izu A, Koen AL, Greffrath J, Fairlie L, Patel F, Mukendi CK, Mbele NJ, Lala R, Burgers WA, Nunes MC, Cutland CL, Gilbert SC, Lambe T, Pollard AJ, Madhi SA. McMahon WC, et al. Among authors: pollard aj. AIDS. 2023 Jan 1;37(1):105-112. doi: 10.1097/QAD.0000000000003414. Epub 2022 Oct 21. AIDS. 2023. PMID: 36476455 Clinical Trial.
Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland.
Ramasamy MN, Kelly EJ, Seegobin S, Dargan PI, Payne R, Libri V, Adam M, Aley PK, Martinez-Alier N, Church A, Jepson B, Khan M, Matthews S, Townsend GT, Vekemans J, Bibi S, Swanson PA 2nd, Lambe T, Pangalos MN, Villafana T, Pollard AJ, Green JA; AZD2816 Study Group. Ramasamy MN, et al. Among authors: pollard aj. Lancet Microbe. 2023 Nov;4(11):e863-e874. doi: 10.1016/S2666-5247(23)00177-5. Epub 2023 Sep 29. Lancet Microbe. 2023. PMID: 37783221 Free article. Clinical Trial.
A SARS-CoV-2 recombinant spike protein vaccine (S-268019-b) for COVID-19 prevention during the Omicron-dominant period: A phase 3, randomised, placebo-controlled clinical trial.
Dinh Thiem V, Van Anh PT, Van Men C, Hung DT, Pollard AJ, Kamitani A, Tada Y, Fukuyama H, Iwasaki Y, Ariyasu M, Sonoyama T. Dinh Thiem V, et al. Among authors: pollard aj. Vaccine. 2024 Jun 20;42(17):3699-3709. doi: 10.1016/j.vaccine.2024.04.084. Epub 2024 May 10. Vaccine. 2024. PMID: 38734495 Free article. Clinical Trial.
Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005).
Koen AL, Izu A, Baillie V, Kwatra G, Cutland CL, Fairlie L, Padayachee SD, Dheda K, Barnabas SL, Bhorat QE, Briner C, Ahmed K, Bhikha S, Bhiman JN, du Plessis J, Esmail A, Horne E, Hwa SH, Oommen-Jose A, Lambe T, Laubscher M, Malahleha M, Benade G, McKenzie S, Oelofse S, Patel F, Pillay S, Rhead S, Rodel H, Taoushanis C, Tegally H, Thombrayil A, Villafana TL, Gilbert S, Pollard AJ, Madhi SA. Koen AL, et al. Among authors: pollard aj. Vaccine. 2023 May 26;41(23):3486-3492. doi: 10.1016/j.vaccine.2023.04.058. Epub 2023 Apr 27. Vaccine. 2023. PMID: 37149443 Free PMC article. Clinical Trial.
Co-producing Human and Animal Experimental Subjects: Exploring the Views of UK COVID-19 Vaccine Trial Participants on Animal Testing.
Vanderslott S, Palmer A, Thomas T, Greenhough B, Stuart A, Henry JA, English M, Naude RW, Patrick-Smith M, Douglas N, Moore M, Hodgson SH, Emary KRW, Pollard AJ. Vanderslott S, et al. Among authors: pollard aj. Sci Technol Human Values. 2023 Jul;48(4):909-937. doi: 10.1177/01622439211057084. Epub 2021 Nov 15. Sci Technol Human Values. 2023. PMID: 37529348 Free PMC article.
Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.
Dejnirattisai W, Huo J, Zhou D, Zahradník J, Supasa P, Liu C, Duyvesteyn HME, Ginn HM, Mentzer AJ, Tuekprakhon A, Nutalai R, Wang B, Dijokaite A, Khan S, Avinoam O, Bahar M, Skelly D, Adele S, Johnson SA, Amini A, Ritter T, Mason C, Dold C, Pan D, Assadi S, Bellass A, Omo-Dare N, Koeckerling D, Flaxman A, Jenkin D, Aley PK, Voysey M, Clemens SAC, Naveca FG, Nascimento V, Nascimento F, Fernandes da Costa C, Resende PC, Pauvolid-Correa A, Siqueira MM, Baillie V, Serafin N, Ditse Z, Da Silva K, Madhi S, Nunes MC, Malik T, Openshaw PJ, Baillie JK, Semple MG, Townsend AR, Huang KA, Tan TK, Carroll MW, Klenerman P, Barnes E, Dunachie SJ, Constantinides B, Webster H, Crook D, Pollard AJ, Lambe T; OPTIC consortium; ISARIC4C consortium; Paterson NG, Williams MA, Hall DR, Fry EE, Mongkolsapaya J, Ren J, Schreiber G, Stuart DI, Screaton GR. Dejnirattisai W, et al. Among authors: pollard aj. bioRxiv [Preprint]. 2021 Dec 22:2021.12.03.471045. doi: 10.1101/2021.12.03.471045. bioRxiv. 2021. PMID: 34981049 Free PMC article. Updated. Preprint.
1,264 results